- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Meyer Handelman Co. Boosts AbbVie Stock Holdings
Institutional investor increases position in pharmaceutical giant by 3.8% in Q4 2025
Apr. 1, 2026 at 10:25am
Got story updates? Submit your updates here. ›
Meyer Handelman Co., an institutional investor, has increased its position in AbbVie Inc. (NYSE: ABBV) by 3.8% in the fourth quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission. The investor now owns 176,495 shares of the pharmaceutical company's stock, valued at approximately $40.3 million.
Why it matters
AbbVie is a major player in the pharmaceutical industry, known for its blockbuster drugs like Humira. This increase in holdings by Meyer Handelman Co. suggests the institutional investor sees continued growth potential in AbbVie's stock, despite broader market volatility.
The details
According to the 13F filing, Meyer Handelman Co. acquired an additional 6,531 shares of AbbVie during the fourth quarter of 2025, bringing its total position to 176,495 shares. This represents approximately 1.3% of the investor's overall portfolio, making AbbVie the 23rd largest holding.
- Meyer Handelman Co. filed its 13F report for the fourth quarter of 2025 on April 1, 2026.
The players
Meyer Handelman Co.
An institutional investor that manages a diversified portfolio of stocks, including a 1.3% position in pharmaceutical giant AbbVie Inc.
AbbVie Inc.
A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.
The takeaway
This filing highlights the continued institutional interest in AbbVie's stock, as the company navigates a competitive pharmaceutical landscape and works to expand its drug pipeline. The increase in holdings by Meyer Handelman Co. suggests the investor sees long-term value in AbbVie's business model and growth prospects.
